18202416Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ, Children's Oncology Group StudyJournal of clinical oncology : official journal of the American Society of Clinical OncologyAngiogenesis Inhibitors; Antibodies, Monoclonal; NeoplasmsAdolescent; Adult; Antibodies, Monoclonal, Humanized; Area Under Curve; Bevacizumab; Child; Child, Preschool; Female; Half-Life; Humans; Infant; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Staging; Risk Factors; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor APhase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.J Clin Oncol2008-01-20T00:00:002008Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000293Living Beings111389680.400538AdolescentD000328Living Beings1578255770.254432AdultD000911Chemicals & Drugs33713760.622749Antibodies, MonoclonalD002648Living Beings93969130.440034ChildD002675Living Beings65236080.594942Child, PreschoolD006207Concepts & Ideas61960.98167Half-LifeD007223Living Beings60430360.61304InfantD007262Procedures1654290.917541Infusions, IntravenousD009367Concepts & IdeasProcedures34719320.670065Neoplasm StagingD005260Physiology1992444050.191167FemaleD012307Concepts & Ideas94153970.464223Risk FactorsD006801Living Beings2262862810.130052HumansJessica J.KandelJessica J. Kandel0.000000000000000.000000000000002889Kandel, Jessica J.ProfessorD008297Physiology1931408600.201617MaleD016896Concepts & Ideas101179490.402389Treatment OutcomeD020533Chemicals & DrugsPhysiology1073090.812499Angiogenesis InhibitorsD019540Concepts & Ideas1513340.923062Area Under CurveD061067Chemicals & Drugs2139290.656166Antibodies, Monoclonal, HumanizedD015996Concepts & Ideas45518560.724887Survival RateD042461Chemicals & Drugs1564070.844293Vascular Endothelial Growth Factor AD000068258732810.891431BevacizumabD009369Disorders55628890.33847NeoplasmsD020714Concepts & Ideas902700.919873Maximum Tolerated DoseSurgeryUniversity of Chicagotrue1ProfessorProfessorAuthorship 77385150.08141190.08141191authors10.2522has subject area